{"drugs":["Varicella Virus Vaccine","Varivax","Zostavax"],"mono":{"0":{"id":"923312-s-0","title":"Generic Names","mono":"Varicella Virus Vaccine"},"1":{"id":"923312-s-1","title":"Dosing and Indications","sub":{"0":{"id":"923312-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Herpes zoster, Zostavax(R); Prophylaxis:<\/b> (50 years or older) 0.65 mL (entire contents of vial) SUBQ; US Food and Drug Administration recommends vaccination starting at age 50 years; Advisory Committee on Immunization Practices recommends vaccination starting at 60 years or older, regardless of prior episodes of herpes zoster<\/li><li><b>Varicella, Varivax(R); Prophylaxis:<\/b> 0.5 mL SUBQ x 2 doses; allow at least 4 weeks to elapse between doses<\/li><\/ul>"},"1":{"id":"923312-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>Zostavax(R) is not for use in children and adolescents<\/li><li><b>Varicella, Varivax(R); Prophylaxis:<\/b> (12 months to 12 years) 0.5 mL SUBQ; allow at least 3 months to elapse if a second 0.5-mL dose is given; the first dose is recommended at 12 to 15 months, and a second dose at 4 to 6 years or before age 4 years if at least 3 months have passed since first dose<\/li><li><b>Varicella, Varivax(R); Prophylaxis:<\/b> (13 years or older) 0.5 mL SUBQ x 2 doses; allow at least 4 weeks to elapse between doses<\/li><\/ul>"},"3":{"id":"923312-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Herpes zoster, Zostavax(R); Prophylaxis<\/li><li>Varicella, Varivax(R); Prophylaxis<\/li><\/ul>"}}},"3":{"id":"923312-s-3","title":"Contraindications\/Warnings","sub":[{"id":"923312-s-3-9","title":"Contraindications","mono":"<ul><li>active febrile infection or febrile respiratory illness (Varivax(R)); consider deferring vaccination in the presence of acute febrile illness (Zostavax(R)); acute illness with or without fever, moderate or severe; defer vaccination unless the benefit of protection outweighs the risk of an adverse reaction (CDC)<\/li><li>anaphylactoid or anaphylactic reaction to neomycin, gelatin, or any other component of vaccine, history (contact dermatitis to neomycin is not a contraindication) (Zostavax(R))<\/li><li>anaphylactoid reaction to neomycin or hypersensitivity to any component of the vaccine, including gelatin (Varivax(R))<\/li><li>bone marrow or lymphatic disorders, including blood dyscrasias, leukemia, lymphomas of any type, and other malignant neoplasms affecting the bone marrow or lymphatic systems<\/li><li>concomitant chemotherapy or radiation therapy; live vaccine should not be administered for at least 3 months unless benefit outweighs risk of adverse reactions<\/li><li>concomitant immunosuppressive therapy, including immunosuppressive doses of corticosteroids (manufacturer); long-term corticosteroid therapy (prednisolone 20 mg or 2 mg\/kg daily or equivalent corticosteroid for 2 weeks or longer) (CDC)<\/li><li>congenital or hereditary immunodeficiency, family history; unless the immune competence of the potential vaccine recipient is demonstrated (Varivax(R))<\/li><li>HIV-associated infections and AIDS (manufacturer); HIV with severe immunocompromise (CDC)<\/li><li>immunodeficiency, primary or acquired, including cellular immune deficiencies, and hypogammaglobulinemic\/dysgammaglobulinemic states<\/li><li>pregnancy; avoid pregnancy for 3 months following vaccination<\/li><li>tuberculosis, active and untreated (Varivax(R)); defer vaccination (Zostavax(R))<\/li><\/ul>"},{"id":"923312-s-3-10","title":"Precautions","mono":"<ul><li>Zostavax(R) is not a substitute for Varivax(R); Zostavax(R) should NOT be used in children and adolescents or for the prevention of primary varicella infection (chickenpox)<\/li><li>anaphylactic or anaphylactoid reaction may occur<\/li><li>antibody-containing products; blood or plasma transfusions or immune globulin administration within previous 11 months (specific interval depends on product)<\/li><li>concomitant use of salicylates or salicylate-containing products in children and adolescents (12 months to 17 years); avoid for  6 weeks after vaccination (Varivax(R))<\/li><li>concomitant use of Zostavax(R) and pneumococcal polyvalent vaccine (Pneumovax(R) 23) should not be given concurrently<\/li><li>immune globulin including varicella zoster immune globulin administration within the previous 5 months or 2 months postvaccination (Varivax(R))<\/li><li>transmission of vaccine virus may occur rarely between vaccinees and susceptible contacts; avoid close association for 6 weeks postvaccination with pregnant women who have not had chickenpox, all newborn infants born at less than 28 weeks gestation, newborn infants of mothers who have not had chickenpox, or individuals with immunodeficiencies<\/li><li>women with childbearing potential; avoid pregnancy for 3 months following vaccination (Varivax(R))<\/li><li>report suspected adverse events to Merck &amp; Co., Inc. at 1-877-888-4231, the Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967, www.fda.gov\/vaers, or www.vaers.hhs.gov<\/li><\/ul>"},{"id":"923312-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"923312-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"923312-s-4","title":"Drug Interactions","sub":{"1":{"id":"923312-s-4-14","title":"Major","mono":"<ul><li>Aclarubicin (established)<\/li><li>Adalimumab (theoretical)<\/li><li>Aldesleukin (established)<\/li><li>Alemtuzumab (established)<\/li><li>Altretamine (established)<\/li><li>Amonafide (established)<\/li><li>Amsacrine (established)<\/li><li>Asparaginase (established)<\/li><li>Aspirin (probable)<\/li><li>Azacitidine (established)<\/li><li>Azathioprine (established)<\/li><li>Balsalazide (probable)<\/li><li>Benorilate (probable)<\/li><li>Bleomycin (established)<\/li><li>Broxuridine (established)<\/li><li>Busulfan (established)<\/li><li>Capecitabine (established)<\/li><li>Carboplatin (established)<\/li><li>Carmustine (established)<\/li><li>Certolizumab Pegol (theoretical)<\/li><li>Chlorambucil (established)<\/li><li>Choline Magnesium Trisalicylate (probable)<\/li><li>Cisplatin (established)<\/li><li>Cladribine (established)<\/li><li>Cyclophosphamide (established)<\/li><li>Cyclosporine (theoretical)<\/li><li>Cytarabine (established)<\/li><li>Cytarabine Liposome (established)<\/li><li>Dacarbazine (established)<\/li><li>Dactinomycin (established)<\/li><li>Daunorubicin (established)<\/li><li>Daunorubicin Citrate Liposome (established)<\/li><li>Decitabine (established)<\/li><li>Docetaxel (established)<\/li><li>Doxifluridine (established)<\/li><li>Doxorubicin (established)<\/li><li>Doxorubicin Hydrochloride Liposome (established)<\/li><li>Edatrexate (established)<\/li><li>Eflornithine (established)<\/li><li>Epirubicin (established)<\/li><li>Estramustine (established)<\/li><li>Etanercept (established)<\/li><li>Etoposide (established)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Floxuridine (established)<\/li><li>Fludarabine (established)<\/li><li>Fluorouracil (established)<\/li><li>Fotemustine (established)<\/li><li>Gallium Nitrate (established)<\/li><li>Gemcitabine (established)<\/li><li>Golimumab (theoretical)<\/li><li>Hydroxyurea (established)<\/li><li>Idarubicin (established)<\/li><li>Ifosfamide (established)<\/li><li>Immune Globulin (probable)<\/li><li>Infliximab (theoretical)<\/li><li>Irinotecan (established)<\/li><li>Lomustine (established)<\/li><li>Mechlorethamine (established)<\/li><li>Melphalan (established)<\/li><li>Mercaptopurine (established)<\/li><li>Mesalamine (probable)<\/li><li>Methotrexate (established)<\/li><li>Mitolactol (established)<\/li><li>Mitomycin (established)<\/li><li>Mitotane (established)<\/li><li>Mitoxantrone (established)<\/li><li>Mycophenolic Acid (theoretical)<\/li><li>Olsalazine (probable)<\/li><li>Oxaliplatin (established)<\/li><li>Paclitaxel (established)<\/li><li>Pegaspargase (established)<\/li><li>Pentostatin (established)<\/li><li>Pipobroman (established)<\/li><li>Pirarubicin (established)<\/li><li>Plicamycin (established)<\/li><li>Pneumococcal Vaccine Polyvalent (established)<\/li><li>Procarbazine (established)<\/li><li>Raltitrexed (established)<\/li><li>Rilonacept (theoretical)<\/li><li>Rituximab (established)<\/li><li>Salicylamide (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Secukinumab (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>Sirolimus (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sodium Thiosalicylate (probable)<\/li><li>Streptozocin (established)<\/li><li>Tacrolimus (theoretical)<\/li><li>Teceleukin (established)<\/li><li>Tegafur (established)<\/li><li>Temsirolimus (theoretical)<\/li><li>Teniposide (established)<\/li><li>Teriflunomide (theoretical)<\/li><li>Thioguanine (established)<\/li><li>Thiotepa (established)<\/li><li>Topotecan (established)<\/li><li>Trabectedin (theoretical)<\/li><li>Treosulfan (established)<\/li><li>Trimetrexate (established)<\/li><li>Trofosfamide (established)<\/li><li>Trolamine Salicylate (probable)<\/li><li>Uracil Mustard (established)<\/li><li>Ustekinumab (theoretical)<\/li><li>Vinblastine (established)<\/li><li>Vincristine (established)<\/li><li>Vincristine Sulfate Liposome (established)<\/li><li>Vindesine (established)<\/li><li>Vinorelbine (established)<\/li><\/ul>"},"2":{"id":"923312-s-4-15","title":"Moderate","mono":"<ul><li>Abatacept (probable)<\/li><li>Cytomegalovirus Immune Globulin, Human (probable)<\/li><li>Hepatitis B Immune Globulin (probable)<\/li><li>Leflunomide (established)<\/li><li>Rabies Immune Globulin (probable)<\/li><li>Respiratory Syncytial Virus Immune Globulin, Human (probable)<\/li><li>Tetanus Immune Globulin (probable)<\/li><li>Vaccinia Immune Globulin, Human (probable)<\/li><li>Varicella-Zoster Immune Globulin (probable)<\/li><\/ul>"}}},"5":{"id":"923312-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Erythema at injection site (35.6% to 48.1%), Induration at injection site (1.1%), Injection site pain (34.3% to 53.9%), Injection site pruritus (6.9% to 11.3%), Injection site reaction (19.3% to 63.6%), Rash, varicella-like (0.9% to 5.5%), Swelling at injection site (26.1% to 40.4%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (1% or greater), Constipation (1% or greater), Diarrhea (1% or greater), Loss of appetite (1% or greater), Nausea (1% or greater), Vomiting (1% or greater)<\/li><li><b>Immunologic:<\/b>Lymphadenopathy (1% or greater)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (1% or greater), Myalgia (1% or greater), Stiff neck (1% or greater)<\/li><li><b>Neurologic:<\/b>Headache (1% or greater)<\/li><li><b>Otic:<\/b>Otitis (1% or greater)<\/li><li><b>Psychiatric:<\/b>Feeling nervous, Irritability<\/li><li><b>Respiratory:<\/b>Cough (1% or greater), Respiratory tract infection (1% or greater)<\/li><li><b>Other:<\/b>Fatigue (1% or greater), Fever (1.8% to 15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Henoch-Schoenlein purpura, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Hematologic:<\/b>Thrombocytopenic purpura<\/li><li><b>Immunologic:<\/b>Anaphylaxis, Herpes zoster ophthalmicus<\/li><li><b>Musculoskeletal:<\/b>Polymyalgia rheumatica<\/li><li><b>Neurologic:<\/b>Aseptic meningitis, Cerebrovascular accident, Encephalitis, Febrile seizure (less than 0.1%), Guillain-Barr  syndrome, Ischemic stroke, Seizure, Non-febrile<\/li><li><b>Respiratory:<\/b>Pulmonary edema<\/li><\/ul>"},"6":{"id":"923312-s-6","title":"Drug Name Info","sub":{"0":{"id":"923312-s-6-17","title":"US Trade Names","mono":"<ul><li>Varivax<\/li><li>Zostavax<\/li><\/ul>"},"2":{"id":"923312-s-6-19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"923312-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"923312-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"923312-s-7","title":"Mechanism Of Action","mono":"Systemic: Vaccination with varicella virus vaccine live induces varicella antibodies and a cell-mediated immune response , which produce active immunity against varicella infection .<br\/>"},"9":{"id":"923312-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>Varivax(R), for subQ use only; do not inject intravascularly<\/li><li>Zostavax(R), for subQ use only; do not inject intravascularly or IM<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Varivax(R), use only diluent (0.7 mL) supplied to reconstitute; administer vaccine within 30 minutes of reconstitution<\/li><li>Zostavax(R), use only diluent supplied to reconstitute; to avoid excess foaming, slowly inject the entire content of the diluent into the vial of concentrated vaccine and gently agitate to mix; administer vaccine within 30 minutes of reconstitution; do not freeze reconstituted vaccine<\/li><li>Varivax(R), preferred injection site is the outer aspect of the upper arm (deltoid region) (adolescents and adults) or the anterior lateral thigh<\/li><li>Zostavax(R), administer subQ, preferably in the deltoid region of the upper arm<\/li><li>Zostavax(R), store in the freezer; reconstitute immediately upon removal of freezer; store diluent separately at room temperature or in the refrigerator<\/li><\/ul><\/li><\/ul>"},"11":{"id":"923312-s-11","title":"How Supplied","mono":"<ul><li><b>Varivax<\/b><br\/>Subcutaneous Powder for Solution: 1350 PFU<br\/><\/li><li><b>Zostavax<\/b><br\/>Subcutaneous Powder for Solution: 19400 PFU<br\/><\/li><\/ul>"},"13":{"id":"923312-s-13","title":"Clinical Teaching","mono":"<ul><li>For up to 6 weeks after vaccination, patient should avoid close contact with immunocompromised individuals, or pregnant women and newborn infants whose mothers have not had chickenpox.<\/li><li>Female patients should avoid getting pregnant for 3 months after receiving vaccination.<\/li><li>This drug may cause fever.<\/li><li>Instruct patient to report varicella-like rash or signs\/symptoms of Stevens-Johnson syndrome (flu-like symptoms, spreading red rash, or skin\/mucous membrane blistering) or toxic epidermal necrolysis (widespread peeling\/blistering of skin).<\/li><li>Patient should avoid using varicella zoster immune globulin or other immune globulin for at least 2 months after receiving vaccination.<\/li><li>Advise pediatric patients to avoid using salicylates or aspirin-containing medicine for 6 weeks after vaccination, as these patients are at higher risk for Reye's syndrome.<\/li><li>Instruct patient to contact healthcare professional for instructions if second shot (booster) is missed.<\/li><\/ul>"}}}